Cogent Biosciences, Inc. (COGT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $31.91: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Cogent Biosciences is a clinical-stage precision oncology biotech whose entire value is concentrated in bezuclastinib, a selective KIT D816V inhibitor targeting systemic mastocytosis and gastrointestinal stromal tumors (GIST). NDAs were submitted for NonAdvSM (Dec 2025) and GIST... Read more
Sell if holding. Engine safety override at $31.91: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Cogent Biosciences, Inc.
Latest news
- NEWS Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target — benzinga May 29, 2026 positive
- NEWS Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUF — benzinga May 28, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55 — benzinga May 6, 2026 positive
- NEWS Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate — benzinga May 5, 2026 positive
- NEWS Cogent Biosciences Announces That Results From Its Phase 3 PEAK Trial Have Been Selected For Oral Presentation At The 20 — benzinga Apr 21, 2026 positive
Generated 2026-06-09T22:16:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebezuclastinib10-K Item 1A: 'Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $31.91: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $29.94. Score 5.0/10, moderate confidence.
Take-profit target: $47.20 (+48.0% upside). Prior stop was $29.94. Stop-loss: $29.94.
Concentration risk — Pipeline: bezuclastinib; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.0), Material insider selling (5 sells, 0.10% of cap).
Cogent Biosciences, Inc. trades at a P/E of N/A (forward -32.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover COGT with a consensus score of 4.3/5. Average price target: $54.
What does Cogent Biosciences, Inc. do?Cogent Biosciences is a clinical-stage precision oncology biotech whose entire value is concentrated in bezuclastinib,...
Cogent Biosciences is a clinical-stage precision oncology biotech whose entire value is concentrated in bezuclastinib, a selective KIT D816V inhibitor targeting systemic mastocytosis and gastrointestinal stromal tumors (GIST). NDAs were submitted for NonAdvSM (Dec 2025) and GIST (Jan-Apr 2026) with a PDUFA date of July 11, 2026 for GIST; commercial launch expected second half 2026 pending FDA approval.